Ehave Provides Progress Update on Its HPPD Study With University of Melbourne
Ehave Provides Progress Update on Its HPPD Study With University of Melbourne
The first stage of the study identified a battery of visual tasks to cover a broad assessment of optical processing that included a pilot comprised of visual tasks and survey questions in approximately 300 undergraduate students. Participants were 18-41 years old with a median age of 20. Approximately 15% the sample had taken psychedelics recreationally, and almost 80% of the sample reported some form of visual disturbance.Potential of monetizing HPPD research by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelics
HPPD研究貨幣化的潛力，通過識別生物標記物來確定服用迷幻劑後患HPPD風險更高的個體
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to announce it has completed the first phase of its series of studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). On July 2, 2021, the Company entered into the Research Project Agreement with The University of Melbourne to gather data and bio-markers to target HPPD, characterized by prolonged or reoccurring perceptual symptoms reminiscent of acute hallucinogen effects, panic attacks and depression.
邁阿密，2023年2月2日(環球網)--EHAVE，Inc.(場外交易代碼：EHVVF)(以下簡稱“公司”)，一家在迷幻和精神健康領域感興趣的醫療分析提供商，高興地宣佈，它已經完成了與墨爾本大學合作的一系列研究的第一階段，以確定迷幻素持續型知覺障礙(HPPD)的原因和可能的治療方法。2021年7月2日，該公司與墨爾本大學簽訂了研究項目協議，以收集數據和生物標記物來針對HPPD，其特徵是長期或反覆出現的感知症狀，使人聯想到急性迷幻劑效應、恐慌症發作和抑鬱。
The HPPD study with the University of Melbourne marks one of several strategic transactions that Ehave has completed in recent months to support its research and development pipeline of active psychedelic-based and potential clinical programs for mental health. Ehave is exploring the potential of monetizing its HPPD research by developing a cure that extends beyond psychedelics by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelics. HPPD, also known as a "bad trip," causes individuals to have recurring visual disturbances recalling only the part of the psychedelic experience that involved visions. This can cause anxiety and affect a person's vision. As many as 5% of LSD users report some version of HPPD and serious cases could be as frequent as 1 in every 100 users of psychedelics. HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. The study is expected to last 12 months and consist of three stages.
HPPD與墨爾本大學的研究標誌着eE近幾個月來完成的幾項戰略交易之一，這些交易是為了支持其積極的迷幻劑和潛在的精神健康臨牀項目的研發流程。EHave正在探索將其HPPD研究貨幣化的潛力，方法是開發一種超越迷幻藥物的治療方法，方法是識別生物標記物，以識別如果服用迷幻藥物，誰患HPPD的風險更高。HPPD，也被稱為“糟糕的旅行”，會導致人們反覆出現視力障礙，只回憶起涉及幻覺的那部分經歷。這會引起焦慮，影響人的視力。多達5%的LSD使用者報告了某種版本的HPPD，嚴重病例的發生率可能高達每100名迷幻劑使用者中就有1人。HPPD最常見的原因是LSD和蘑菇，但也可以由MDMA、大麻，甚至SSRIs引起。這項研究預計將持續12個月，包括三個階段。
The first stage of the study identified a battery of visual tasks to cover a broad assessment of optical processing that included a pilot comprised of visual tasks and survey questions in approximately 300 undergraduate students. Participants were 18-41 years old with a median age of 20. Approximately 15% the sample had taken psychedelics recreationally, and almost 80% of the sample reported some form of visual disturbance.
這項研究的第一階段確定了一系列視覺任務，以涵蓋對光學處理的廣泛評估，其中包括一項由視覺任務和對大約300名本科生的調查問題組成的試點。受試者年齡在18-41歲之間，中位年齡20歲。大約15%的樣本服用過迷幻劑，幾乎80%的樣本報告了某種形式的視覺障礙。
The phase one testing process results indicated a much higher incidence of visual disturbances in people with no diagnosis of HPPD. These results are consistent with recent research in visual snow, similar to HPPD but requires no history of drug use for the diagnosis. The study also found a high incidence of visual disturbances linked to non-psychedelic drugs, along with evidence suggesting a potential link between participants' discomfort and distress from visual disturbances and mental health, such as anxiety and depression, as well as migraines. The data from phase one of our testing process is from the University of Melbourne undergraduate sample, not the HPPD community. Phase two of the trial will include a more extensive participant base, specifically from the HPPD community. We believe the risk factors of HPPD will be linked more to a history of anxiety, depression, and migraine, suggesting people with such conditions have a higher risk of developing HPPD if they take psychedelics.
第一階段的測試結果表明，在沒有診斷出HPPD的人中，視力障礙的發生率要高得多。這些結果與最近對視覺雪的研究一致，視覺雪類似於HPPD，但不需要藥物使用史來診斷。研究還發現，與非迷幻藥物有關的視力障礙的發生率很高，同時有證據表明，參與者因視力障礙而感到的不適和痛苦與心理健康(如焦慮、抑鬱以及偏頭痛)之間存在潛在聯繫。我們測試過程第一階段的數據來自墨爾本大學本科生樣本，而不是HPPD社區。試驗的第二階段將包括更廣泛的參與者基礎，特別是來自HPPD社區的參與者。我們認為HPPD的危險因素將更多地與焦慮、抑鬱和偏頭痛的病史聯繫在一起，這表明患有這些疾病的人如果服用迷幻劑，患HPPD的風險更高。
Ben Kaplan, CEO of Ehave, said, "Ehave's goal in completing phase one of this study with the University of Melbourne was to develop data for our active psychedelic-based and potential clinical programs for mental health. We are very pleased with the progress so far. Ehave intends to be the industry leader in preventing negative side effects during treatment for mental health issues." Mr. Kaplan continued, "Our goal is to be the Company that prevents individuals from suffering from a lifetime of flashbacks after being treated for mental health issues with these powerful molecules. We believe determining the cause of HPPD and finding a possible cure will help us better understand these molecules as a whole."
EHave的首席執行官本·卡普蘭説：“eHave在墨爾本大學完成這項研究的第一階段的目的是為我們積極的基於迷幻藥物的和潛在的精神健康臨牀項目開發數據。我們對目前的進展非常滿意。我們打算在預防精神健康問題治療過程中的負面副作用方面成為行業領導者。”卡普蘭先生繼續説道：“我們的目標是成為這家公司，防止人們在接受這些強大分子的精神健康治療後，終生閃回。我們相信，確定HPPD的原因並找到可能的治療方法將有助於我們更好地瞭解這些分子作為一個整體。”
About Ehave, Inc.
關於eHave公司
Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: .
EHave是一家領先的醫療服務和技術公司，專注於通過設計新的化合物和新的治療方案來治療大腦健康，從而促進迷幻藥物到治療的進展。我們與我們的科學家和精神健康專業人員網絡一起，肩負着為患者創造安全有效的治療方法的使命，以解決大量的精神健康問題，利用臨牀數據幫助我們實現最佳的患者結果。EHave的業務遍及整個美國、加拿大、牙買加和澳大利亞。欲瞭解更多有關eHave的信息，請訪問公司網站：
Forward-Looking Statement Disclaimer
前瞻性聲明免責聲明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,
本新聞稿包含“1995年私人證券訴訟改革法”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設，會受到各種已知和未知的風險和不確定性的影響，其中許多風險和不確定性是公司無法控制的，無法預測或量化，因此，實際結果可能與此類前瞻性陳述中明示或暗示的結果大不相同：(1)公司研究、製造和其他開發工作的發起、時間、進展和結果；(2)公司推進其產品成功完成開發和商業化的能力；(3)製造、開發、商業化的能力；(3)公司的能力。, (V)公司行業內具有競爭力的公司和技術以及引入競爭產品的能力；(Vi)公司建立和維持公司合作的能力；(Vii)主要管理人員的流失；(Viii)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力；(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律；以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求，否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更多詳細信息，包含在eHave，Inc.於2015年9月24日提交給美國證券交易委員會(美國證券交易委員會)的經修訂的F-1表格註冊説明書中的“風險因素”標題下，該説明書可在美國證券交易委員會的網站上獲得。
For Media and Investor Relations, please contact:
媒體和投資者關係，請聯繫:
David L. Kugelman
David·L·庫格曼
(866) 692-6847 Toll Free - U.S. & Canada
(866)692-6847免費-美國和加拿大
(404) 281-8556 Mobile and WhatsApp
(404)281-8556移動電話和WhatsApp
Email: Ir@Ehave.com
電子郵件：ir@ehave.com
Skype: kugsusa
Skype：kugsusa
LinkedIn:
LinkedIn：
譯文內容由第三人軟體翻譯。
